summary
Harnessing the body’s own immune system to fight cancer has long been a dream. After decades of disappointments, the tide has recently changed due to the success of recent proof-of-concept clinical trials. Most notably have been the advances made with CTLA4 and PD-1 inhibition in patients with advanced melanoma. These findings formed the spark for a flood of clinical trials evaluating a plethora of immunotherapeutic agents in all imaginable tumor types. During the 2015 annual meeting of the European Hematology Association, Bristol-Myers Squibb organized a satellite symposium assessing the potential of immunotherapy in the treatment of lymphoma and multiple myeloma.
(BELG J HEMATOL 2015;6(3): 108–10)
